Weight Management

 
Where is All the Wegovy Going? Highest and Lowest Prescribing States
January 22, 2024

The GLP-1 RAs Wegovy, Ozempic, Mounjaro, and Zepbound have taken up more real estate on the US map in some areas than others. Click to find out more.

"Ozempic" and Older Adults: Awareness of & Views on Rx Medications for Weight Management
January 19, 2024

When it comes overweight, obesity, and prescription drugs for weight loss, these results from the National Poll on Healthy Aging suggest older US adults need guidance.

Nonprescription Weight Loss Products Used by 1 in 10 Adolescents Worldwide: New Meta-Analysis
January 17, 2024

Use of nonprescribed weight loss products was higher among girls than boys globally and led by diet pills, followed by laxatives and diuretics, a meta-analysis found.

Daily Dose: NAFLD Associated with Adverse Outcomes Regardless of BMI
January 16, 2024

Your daily dose of the clinical news you may have missed.

FDA Review Suggest No Link Between GLP-1RAs and Suicidal Thoughts but Surveillance Will Continue
January 12, 2024

While the FDA's preliminary evaluation has not surfaced evidence of a link, the agency says it "cannot definitively rule out that a small risk may exist," and so will continue research.

NAFLD Linked to Adverse Outcomes Regardless of BMI, New Research Suggests
January 08, 2024

Individuals with "lean NAFLD" may be at similar risk of NASH, cirrhosis, nonliver cancer, and death as as those with NAFLD and overweight or obesity, authors say.

Eli Lilly Open Letter Warns Against Use of Tirzepatide for "Cosmetic Weight Loss"
January 05, 2024

In an open letter to the public, Lilly decries use of tirzepatide products Mounjaro and Zepbound for nonmedical purposes and warns of counterfeit formulations.

Daily Dose: Tirzepatide Discontinuation Results in Weight Regain
December 19, 2023

Your daily dose of the clinical news you may have missed.

Obesity Medicine Certificates Increase 40% from 2022 to 2023, says ABOM
December 18, 2023

The American Board of Obesity Medicine says annual first-time certificates now exceed those for cardiology, pulmonology, and medical oncology.

Tirzepatide Demonstrates Sustained Weight Loss but Discontinuation Results in Weight Regain: SURMOUNT-4 Trial
December 13, 2023

Study participants randomized to placebo for 1 year after 36 weeks on tirzepatide had mean weight regain of 14% vs augmented loss among those who continued on the medication.